Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 20/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 3/20 | 0.83 |
| ▸ | HTR2A | P28223 | 3/20 | 0.83 |
| ▸ | HTR2C | P28335 | 3/20 | 0.83 |
| ▸ | HTR2B | P41595 | 3/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.83 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.83 |
| ▸ | MTOR | P42345 | 1/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | BLM | P54132 | 1/20 | 0.81 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3817479 | 0.91 | SIGMAR1 (0.84) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL467191 | 0.91 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL29802790 | 0.91 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7380092 | 0.90 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL29725559 | 0.90 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| Fumaric Acid SCHEMBL29766849 | 0.89 | SIGMAR1 (0.80) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| Maleic Acid SCHEMBL29761658 | 0.89 | SIGMAR1 (0.80) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1587654 | 0.88 | SIGMAR1 (0.79) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9311626 | 0.88 | SIGMAR1 (1.00) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1587585 | 0.88 | SIGMAR1 (0.79) | SIGMAR1TP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| EP-0445974-A2 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-09-11 | — | — | EP | claimed |
| JP-4211662-A | — | — | None | — | — | JP | disclosed |
| EP-2600863-B1 | USE OF SIGMA LIGANDS IN OPIOID-INDUCED HYPERALGESIA | ESTEVE LABOR DR (ES) | 2018-03-28 | — | — | EP | disclosed |
| US-9844516-B2 | Sigma ligands for use in the prevention and/or treatment of post-operative pain | Laboratorios De Dr. Esteve (ES) | 2017-12-19 | — | — | US | disclosed |
| US-9789115-B2 | Use of sigma ligands in opioid-induced hyperalgesia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2017-10-17 | — | — | US | disclosed |
| US-9782483-B2 | Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy | LABORATORIES DEL DR. ESTEVE, S.A. (ES) | 2017-10-10 | — | — | US | disclosed |
| EP-2646025-B1 | USE OF SIGMA LIGANDS IN BONE CANCER PAIN | ESTEVE LABOR DR (ES) | 2017-03-15 | — | — | EP | disclosed |
| EP-2531191-B1 | Sigma ligands for use in the prevention and/or treatment of postoperative pain | ESTEVE LABOR DR (ES) | 2016-03-30 | — | — | EP | disclosed |
| EP-2571501-B1 | SIGMA LIGANDS FOR THE PREVENTION AND/OR TREATMENT OF EMESIS INDUCED BY CHEMOTHERAPY OR RADIOTHERAPY | ESTEVE LABOR DR (ES) | 2016-03-02 | — | — | EP | disclosed |
| US-9034798-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | CAPROTEC BIOANALYTICS GMBH (DE) | 2015-05-19 | — | — | US | disclosed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
| US-5554752-A | SPIRO FUSED PIPERIDINES CAPABLE OF BINDING TO A VESAMICOL RECEPTOR AND HAVING ANTICHOLINERGIC PROPERTIES | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1996-09-10 | — | — | US | disclosed |
| US-5457207-A | Anticholinergic agents | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 1995-10-10 | — | — | US | disclosed |
| US-5324733-A | Selective ligands at sigma recognition sites | MERCK SHARPE & DOHME LTD. | 1994-06-28 | — | — | US | disclosed |
| US-5219860-A | Neuroleptic agents | MERCK SHARP & DOHME LIMITED (GB) | 1993-06-15 | — | — | US | disclosed |
| JP-H04211662-A | SPIROCYCLIC ANTIPSYCHOTIC AGENT | MERCK SHARP & DOHME LTD | 1992-08-03 | — | — | JP | disclosed |
| EP-0445974-A2 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | SIGMAR1 521/4885TP53 3839/4885CYP1A2 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.